Terms: = Pancreatic cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Prognosis
44 results:
1. High-grade Solid Pseudopapillary Neoplasms of the Pancreas: Distinct Clinicopathological Malignant Features With Intriguing Gene Alterations through a Comparison With the Conventional Type.
Honda S; Yamaguchi H; Aimono E; Hara S; Minamiguchi S; Norose T; Ohike N; Yamochi T; Yasuda M; Moriya T; Shiko Y; Nishihara H; Nagao T
Am J Surg Pathol; 2024 Mar; 48(3):353-363. PubMed ID: 38189381
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and Functional Heterogeneity of Primary pancreatic Neuroendocrine Tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
Centonze G; Maisonneuve P; Prinzi N; Pusceddu S; Albarello L; Pisa E; Barberis M; Vanoli A; Spaggiari P; Bossi P; Cattaneo L; Sabella G; Solcia E; La Rosa S; Grillo F; Tagliabue G; Scarpa A; Papotti M; Volante M; Mangogna A; Del Gobbo A; Ferrero S; Rolli L; Roca E; Bercich L; Benvenuti M; Messerini L; Inzani F; Pruneri G; Busico A; Perrone F; Tamborini E; Pellegrinelli A; Kankava K; Berruti A; Pastorino U; Fazio N; Sessa F; Capella C; Rindi G; Milione M
Neuroendocrinology; 2023; 113(4):457-469. PubMed ID: 36417840
[TBL] [Abstract] [Full Text] [Related]
4. Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites.
Sun TY; Zhao L; Van Hummelen P; Martin B; Hornbacker K; Lee H; Xia LC; Padda SK; Ji HP; Kunz P
Endocr Relat Cancer; 2022 Dec; 29(12):665-679. PubMed ID: 36165930
[TBL] [Abstract] [Full Text] [Related]
5. Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma.
Mafficini A; Simbolo M; Shibata T; Hong SM; Pea A; Brosens LA; Cheng L; Antonello D; Sciammarella C; Cantù C; Mattiolo P; Taormina SV; Malleo G; Marchegiani G; Sereni E; Corbo V; Paolino G; Ciaparrone C; Hiraoka N; Pallaoro D; Jansen C; Milella M; Salvia R; Lawlor RT; Adsay V; Scarpa A; Luchini C
Mod Pathol; 2022 Dec; 35(12):1929-1943. PubMed ID: 36056133
[TBL] [Abstract] [Full Text] [Related]
6. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Significance of
Saed L; Jeleń A; Mirowski M; Sałagacka-Kubiak A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805937
[TBL] [Abstract] [Full Text] [Related]
8. Discovery of a novel NUAK1 inhibitor against pancreatic cancer.
Seo MS; Jung KH; Kim K; Lee JE; Han BS; Ko S; Kim JH; Hong S; Lee SH; Hong SS
Biomed Pharmacother; 2022 Aug; 152():113241. PubMed ID: 35691157
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms.
Taboada R; Claro L; Felismino T; de Jesus VH; Barros M; Riechelmann RP
J Neuroendocrinol; 2022 Apr; 34(4):e13099. PubMed ID: 35174558
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic role of IRS-4 in the survival of patients with pancreatic cancer.
Ortega MA; Pekarek L; Garcia-Montero C; Fraile-Martinez O; Saez MA; Asúnsolo A; Alvarez-Mon MA; Monserrat J; Coca S; Toledo-Lobo MV; García-Honduvilla N; Albillos A; Buján J; Alvarez-Mon M; Guijarro LG
Histol Histopathol; 2022 May; 37(5):449-459. PubMed ID: 35137378
[TBL] [Abstract] [Full Text] [Related]
11. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
[TBL] [Abstract] [Full Text] [Related]
12. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
13. Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma.
Song G; Zhu X; Xuan Z; Zhao L; Dong H; Chen J; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
Theranostics; 2021; 11(5):2318-2333. PubMed ID: 33500727
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract] [Full Text] [Related]
15. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
Arakelyan J; Zohrabyan D; Philip PA
Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
[TBL] [Abstract] [Full Text] [Related]
16. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
[TBL] [Abstract] [Full Text] [Related]
17. pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.
Tanaka H; Hijioka S; Hosoda W; Ueno M; Kobayashi N; Ikeda M; Ito T; Kodama Y; Morizane C; Notohara K; Taguchi H; Kitano M; Komoto I; Tsuji A; Hashigo S; Kanno A; Miyabe K; Takagi T; Ishii H; Kojima Y; Yoshitomi H; Yanagimoto H; Furuse J; Mizuno N
Pancreatology; 2020 Oct; 20(7):1421-1427. PubMed ID: 32891532
[TBL] [Abstract] [Full Text] [Related]
18. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
[TBL] [Abstract] [Full Text] [Related]
19. New addiction to the NRF2-related factor NRF3 in cancer cells: Ubiquitin-independent proteolysis through the 20S proteasome.
Kobayashi A; Waku T
Cancer Sci; 2020 Jan; 111(1):6-14. PubMed ID: 31742837
[TBL] [Abstract] [Full Text] [Related]
20. Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells.
Rencuzogulları O; Yerlikaya PO; Gürkan AÇ; Arısan ED; Telci D
J Cell Biochem; 2020 Jan; 121(1):508-523. PubMed ID: 31264276
[TBL] [Abstract] [Full Text] [Related]
[Next]
